Amgen Inc. AMGN
414.61
8.57
2.11%
as of 25 Sep
- Market cap
- $219.1B
- P/E
- 25.6×
Follow AMGN
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Amgen Inc. (AMGN) Gross margin
Amgen Inc.'s gross margin over the twelve months to 30 June 2026 was 69.5%, up 2.3 percentage points from fiscal 2025 (67.3%). Over the past ten years it has ranged from 61.5% (fiscal 2024) to 82.7% (fiscal 2018); the current reading is higher than 18% of that period. That is in line with the Drug Manufacturers General industry median of 72.8% and above the Healthcare sector median of 53.7%.
Gross margin, annual
Annual
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 67.3% | 5.72 |
| FY2024 | 61.5% | (8.49) |
| FY2023 | 70.0% | (5.64) |
| FY2022 | 75.7% | 0.50 |
| FY2021 | 75.2% | (0.61) |
| FY2020 | 75.8% | (5.58) |
| FY2019 | 81.4% | (1.38) |
| FY2018 | 82.7% | 0.54 |
| FY2017 | 82.2% | 0.29 |
| FY2016 | 81.9% | 1.41 |
Quarterly
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 72.0% | 3.88 |
| Mar 2026 | 68.2% | (1.68) |
| Dec 2025 | 69.8% | 2.09 |
| Sep 2025 | 67.8% | 0.55 |
| 42 more quarters | Free account |
Against its own ten years
Low 61.5%
High 82.7%
Ten-year median
75.8%
Current reading's percentile
18
Gross margin against peers
| Company | Gross margin |
|---|---|
| AZN AstraZeneca PLC compare | 81.9% |
| NVO Novo Nordisk A/S compare | 80.7% |
| GILD Gilead Sciences, Inc. compare | 79.6% |
| NVS Novartis AG compare | 74.7% |
| PFE Pfizer Inc. compare | 73.2% |
| MRK Merck & Co., Inc. compare | 73.0% |
| ABBV AbbVie Inc. compare | 71.5% |
| BMY Bristol Myers Squibb Company compare | 70.2% |
| AMGN Amgen Inc. | 69.5% |
| Drug Manufacturers General industry median | 72.8% |
| Healthcare sector median | 53.7% |
| Market median | 46.3% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on AMGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement